Detalhe da pesquisa
1.
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
Blood
; 134(4): 353-362, 2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31101627
2.
Y90 -Ibritumomab tiuxetan (Y90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).
Hematol Oncol
; 35(4): 576-583, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27677906
3.
Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma.
Support Care Cancer
; 25(9): 2833-2842, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28405846
4.
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
Br J Haematol
; 174(2): 255-63, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27018242
5.
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
Blood
; 132(19): 2097-2100, 2018 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30237154
6.
Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98).
Br J Haematol
; 168(1): 145-8, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25142001
7.
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.
Blood Adv
; 4(23): 5951-5957, 2020 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33275769
8.
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
J Clin Oncol
; 34(5): 495-500, 2016 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26712227
9.
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
Eur J Cancer
; 51(10): 1212-20, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25892646